Superiority of letrozole over tamoxifen in the first-line treatment of metastatic breast cancer patients with normal serum HER-2/neu levels:: question of tamoxifen resistance -: In Reply

被引：0
|
作者：
Lipton, A [1 ]
Leitzel, K
Demers, L
Harvey, HA
Ali, SM
Chaudri-Ross, HA
Wyld, P
Brady, C
Carney, W
机构：
[1] MS Hershey Med Ctr, Hershey, PA USA
[2] Vet Adm Med Ctr, Lebanon, PA USA
[3] Novartis Pharma AG, Basel, Switzerland
[4] Novartis Pharmaceut Corp, E Hanover, NJ USA
[5] Bayer Corp, Tarrytown, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2003年 / 21卷 / 24期
关键词：
D O I：
10.1200/JCO.2003.99.187
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：4657 / 4657
页数：1
相关论文
共 50 条
  • [1] Superiority of letrozole over tamoxifen in the first-line treatment of metastatic breast cancer patients with normal serum HER-2/neu levels:: question of tamoxifen resistance
    Altundag, K
    Altundag, O
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (24) : 4656 - 4656
  • [2] Serum TIMP-1 and HER-2/neu levels in metastatic breast cancer (MBC) treated with either letrozole or tamoxifen
    Hamer, P. J.
    Lipton, A.
    Leitzel, K.
    Demers, L.
    Ali, S. M.
    Evans, D. B.
    Chaudri-Ross, H. A.
    Brown-Shimer, S.
    Pierce, K.
    Carney, W. P.
    Gaur, V.
    CLINICAL CHEMISTRY, 2009, 55 (06) : A156 - A156
  • [3] Serum HER-2/neu conversion to positive at the time of cancer progression in metastatic breast patients treated with letrozole vs. tamoxifen.
    Lipton, A
    Leitzel, K
    Ali, SM
    Demers, L
    Harvey, HA
    Chaudri-Ross, HA
    Lang, R
    Hackl, W
    Hamer, P
    Carney, W
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (23) : 288S - 288S
  • [4] Superiority of letrozole to tamoxifen in the first-line treatment of advanced breast cancer: Evidence from metastatic subgroups and a test of functional ability
    Mouridsen, H
    Sun, Y
    Gershanovich, M
    Perez-Carrion, R
    Becquart, D
    Chaudri-Ross, HA
    Lang, R
    ONCOLOGIST, 2004, 9 (05): : 489 - 496
  • [5] HER-2/neu serum levels vis-a-vis hormonal response in metastatic breast cancer -: Reply
    Lipton, A
    Ali, SM
    Leitzel, K
    Engle, L
    Chinchilli, V
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (15) : 3357 - 3357
  • [6] Tissue expression and serum levels of HER-2/neu in patients with breast cancer
    Krainer, M
    Brodowicz, T
    Zeillinger, R
    Wiltschke, C
    Scholten, C
    Seifert, M
    Kubista, E
    Zielinski, CC
    ONCOLOGY, 1997, 54 (06) : 475 - 481
  • [7] Tissue expression and serum levels of HER-2/neu in patients with breast cancer
    Brodowicz, T
    Krainer, M
    Zeillinger, R
    Budinsky, AC
    Wiltschke, C
    Zielinski, CC
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 657 - 657
  • [8] Correlation of serum HER-2/neu extracellular domain levels in metastatic breast cancer with the expression of HER-2/neu in corresponding primary tumors
    Witzel, I.
    Mueller, V.
    Wiczak, W.
    Bubenheim, W.
    Jaenicke, F.
    Thomssen, C.
    EJC SUPPLEMENTS, 2004, 2 (03): : 178 - 178
  • [9] Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer
    Ali, Suhail M.
    Carney, Walter P.
    Esteva, Francisco J.
    Fornier, Monica
    Harris, Lyndsay
    Koestler, Wolfgang. J.
    Lotz, Jean-Pierre
    Luftner, Diana
    Pichon, Marie-France
    Lipton, Allan
    CANCER, 2008, 113 (06) : 1294 - 1301
  • [10] Advances in First-Line Treatment for Patients with HER-2+ Metastatic Breast Cancer
    De Mattos-Arruda, Leticia
    Cortes, Javier
    ONCOLOGIST, 2012, 17 (05): : 631 - 644
12345